DS
EDIT icon

David Shaw’s Editas Medicine EDIT Stock Holding History

David Shaw’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.16M Sell
1,901,002
-42,891
-2% -$125K ﹤0.01% 2235
2026
Q1 		$4.8M Buy
1,943,893
+834,303
+75% +$1.77M ﹤0.01% 2212
2025
Q4 		$2.27M Buy
1,109,590
+993,411
+855% +$2.87M ﹤0.01% 2948
2025
Q3 		$403K Buy
116,179
+6,066
+6% +$16.9K ﹤0.01% 3970
2025
Q2 		$242K Sell
110,113
-349,587
-76% -$572K ﹤0.01% 3983
2025
Q1 		$533K Buy
459,700
+280,185
+156% +$412K ﹤0.01% 3472
2024
Q4 		$228K Sell
179,515
-5,200
-3% -$13.3K ﹤0.01% 4025
2024
Q3 		$630K Sell
184,715
-366,138
-66% -$1.59M ﹤0.01% 3571
2024
Q2 		$2.57M Sell
550,853
-538,387
-49% -$3.04M ﹤0.01% 2425
2024
Q1 		$8.08M Sell
1,089,240
-98,324
-8% -$817K 0.01% 1527
2023
Q4 		$12M Buy
1,187,564
+518,819
+78% +$4.55M 0.01% 1242
2023
Q3 		$5.22M Sell
668,745
-117,324
-15% -$1.01M 0.01% 1775
2023
Q2 		$6.47M Buy
786,069
+287,279
+58% +$2.5M 0.01% 1673
2023
Q1 		$3.62M Sell
498,790
-8,164
-2% -$72.6K ﹤0.01% 2221
2022
Q4 		$4.5M Buy
506,954
+341,333
+206% +$3.75M 0.01% 2202
2022
Q3 		$2.03M Sell
165,621
-189,204
-53% -$2.95M ﹤0.01% 2994
2022
Q2 		$4.2M Sell
354,825
-278,086
-44% -$3.73M ﹤0.01% 2350
2022
Q1 		$12M Buy
632,911
+269,778
+74% +$5.01M 0.01% 1438
2021
Q4 		$9.64M Buy
363,133
+231,386
+176% +$7.96M 0.01% 1700
2021
Q3 		$5.41M Buy
131,747
+10,582
+9% +$580K ﹤0.01% 2039
2021
Q2 		$6.86M Sell
121,165
-479,643
-80% -$17.7M 0.01% 1789
2021
Q1 		$25.2M Sell
600,808
-808,285
-57% -$46M 0.02% 806
2020
Q4 		$98.8M Buy
1,409,093
+410,086
+41% +$16.8M 0.09% 271
2020
Q3 		$28M Sell
999,007
-277,634
-22% -$9.04M 0.03% 662
2020
Q2 		$37.8M Buy
1,276,641
+233,592
+22% +$6.1M 0.05% 473
2020
Q1 		$20.7M Sell
1,043,049
-365,947
-26% -$9.23M 0.03% 601
2019
Q4 		$41.7M Buy
1,408,996
+431,392
+44% +$10.8M 0.05% 482
2019
Q3 		$22.2M Buy
977,604
+354,273
+57% +$8.78M 0.03% 725
2019
Q2 		$15.4M Buy
623,331
+193,031
+45% +$4.61M 0.02% 890
2019
Q1 		$10.5M Sell
430,300
-36,747
-8% -$832K 0.01% 1078
2018
Q4 		$10.6M Sell
467,047
-4,194
-0.9% -$114K 0.01% 1051
2018
Q3 		$15M Sell
471,241
-79,879
-14% -$2.58M 0.02% 908
2018
Q2 		$19.7M Buy
551,120
+1,685
+0.3% +$59.7K 0.03% 733
2018
Q1 		$18.2M Buy
549,435
+304,317
+124% +$10.8M 0.02% 713
2017
Q4 		$7.53M Buy
245,118
+36,765
+18% +$926K 0.01% 1212
2017
Q3 		$5M Buy
208,353
+36,927
+22% +$703K 0.01% 1375
2017
Q2 		$2.88M Sell
171,426
-73,503
-30% -$1.32M ﹤0.01% 1738
2017
Q1 		$5.47M Buy
244,929
+226,652
+1,240% +$4.7M 0.01% 1232
2016
Q4 		$297K Buy
+18,277
New +$277K ﹤0.01% 3121

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

David Shaw's EDIT Position: Q2 2026 in Review

David Shaw reduced its Editas Medicine (EDIT) stake by 2.2% in Q2 2026, selling an estimated $125K and leaving 1,901,002 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

David Shaw first reported a position in EDIT in Q4 2016 and has held it in 39 quarters since. The position peaked at $98.8M in Q4 2020. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • David Shaw held 1,901,002 shares of Editas Medicine worth $6.16M as of Q2 2026.
  • David Shaw sold 42,891 Editas Medicine shares in Q2 2026, an estimated $125K.
  • Editas Medicine made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2235 holding.
  • David Shaw first reported a position in Editas Medicine in Q4 2016 and has held it in 39 quarters since.
  • David Shaw's Editas Medicine position peaked at $98.8M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.